Granisetron Mylan Generics (Granisetron)

Granisetron Mylan Generics is indicated for the prevention of nausea and vomiting in specific clinical situations.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Prevention of postoperative nausea and vomiting (PONV) following surgical procedures.
• Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated.
• Adjunct therapy for patients receiving radiotherapy who experience nausea.

The safety profile of granisetron includes both frequently observed and less common adverse reactions.

Common

• Headache.
• Constipation.
• Fatigue.
• Dizziness.

Serious

• Allergic reactions such as rash, itching, or swelling.
• Cardiac arrhythmias (rare).
• Severe hypotension.
• Serotonin syndrome when combined with other serotonergic agents.

Before initiating therapy with Granisetron Mylan Generics, clinicians should consider several precautionary factors.

• Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists.
• Use caution in patients with prolonged QT interval or cardiac conduction disorders.
• Evaluate renal and hepatic function, as dose adjustments may be needed in severe impairment.
• Monitor for signs of serotonin syndrome if the patient is receiving other serotonergic drugs.
• Consider pregnancy and breastfeeding status; the safety profile has not been fully established.

Granisetron may interact with other medications, influencing its efficacy or safety.

Avoid

• Concomitant use with other 5‑HT3 antagonists (e.g., ondansetron) is generally unnecessary.
• Combining with drugs that prolong QT interval (e.g., certain antiarrhythmics, antipsychotics) should be avoided.

Use with caution

• Serotonergic agents such as SSRIs, SNRIs, tramadol, or linezolid may increase risk of serotonin syndrome.
• CYP3A4 inhibitors (e.g., ketoconazole) may raise granisetron plasma levels.
• CYP3A4 inducers (e.g., rifampin) may reduce granisetron exposure.